Research progress of fluorescent antibody SGM-101 targeting carcinoembryonic antigen in colorectal surgeryof carcino-embryonic antigen targeting fluorescent antibody SGM-101 in colorectal surgery

doi:10.3877/cma.j.issn.1674-3946.2021.06.033

Abstract

Abstract:

In recent years, with the development of the concept of precision surgery, fluorescence angiographyimaging technology has been widely usedmore and more applied in clinical practice. NeverthnessHowever, most of the clinically used contrast agents are not specific to tumors have problems such as tumor targeting insufficient, which is not conducive to the diagnosis of tumorsfavorable to cancer detecting. So it is of great significance to develop tumor targeting contrast agents. This paper will review the application progress of CEA-targeting fluorescent antibody SGM-101 in colorectal surgery.

Key words: Colorectal neoplasms, Carcinoembryonic antigen, Review, Fluorescent antibody technique

Jingjing Li, Zhipeng Liu, Chengzhang Zhu, Xinlong Shi, Weisheng Zhang, Xiongfei Yang. Research progress of fluorescent antibody SGM-101 targeting carcinoembryonic antigen in colorectal surgeryof carcino-embryonic antigen targeting fluorescent antibody SGM-101 in colorectal surgery[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2021, 15(06): 703-706.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2021.06.033

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2021/V15/I06/703

References 32

[1]	Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality[J]. Gut, 2017, 66(4) : 683-691.
[2]	van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study[J]. Lancet, 2018, 391 (10139) : 2537-2545.
[3]	Al-Sukhni E, Attwood K, Mattson DM, et al. Predictors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer[J]. Ann Surg Oncol, 2016, 23(4) : 1177-1186.
[4]	Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues[J]. Semin Cancer Biol, 1999, 9(2) : 67-81.
[5]	Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system[J]. J Exp Med, 1965, 122(3) : 467-481.
[6]	Boonstra MC, de Geus SWL, Prevoo HAJM, et al. Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins[J]. Biomark Cancer, 2016, 8 : 119-133.
[7]	陈保祥，江从庆，钱群. 吲哚菁绿荧光造影在结直肠外科手术中的应用进展[J/CD]. 中华普外科手术学杂志(电子版)，2020，14(1)：101-105.
[8]	Metildi CA, Kaushal S, Pu M, et al. Fluorescence-guided surgery with a fluorophore-conjugated antibody to carcinoembryonic antigen (CEA), that highlights the tumor, improves surgical resection and increases survival in orthotopic mouse models of human pancreatic cancer[J]. Ann Surg Oncol, 2014, 21(4) : 1405-1411.
[9]	Gutowski M, Framery B, Boonstra MC, et al. SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery[J]. Surg Oncol, 2017, 26(2) : 153-162.
[10]	Meijer RPJ, de Valk KS, Deken MM, et al. Intraoperative detection of colorectal and pancreatic liver metastases using SGM-101, a fluorescent antibody targeting CEA[J]. Eur J Surg Oncol, 2021, 43(3 Pt B) : 667-673.
[11]	Clarke P, Mann J, Simpson JF, et al. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy[J]. Cancer Res, 1998, 58(7) : 1469-1477.
[12]	Framery B, Gutowski M, Dumas K, et al. Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients[J]. Toxicol Rep, 2019, 6 : 409-415.
[13]	Urano Y, Sakabe M, Kosaka N, et al. Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe[J]. Sci Transl Med, 2011, 3(110) : 110ra119.
[14]	Nguyen QT, Tsien RY. Fluorescence-guided surgery with live molecular navigation--a new cutting edge[J]. Nat Rev Cancer, 2013, 13(9) : 653-662.
[15]	Boogerd LSF, Hoogstins CES, Schaap DP, et al. Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study[J]. Lancet Gastroenterol Hepatol, 2018, 3(3) : 181-191.
[16]	de Valk KS, Deken MM, Schaap DP, et al. Dose-Finding Study of a CEA-Targeting Agent, SGM-101, for Intraoperative Fluorescence Imaging of Colorectal Cancer[J]. Ann Surg Oncol, 2020, 28(4) : 1-13.
[17]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6) : 394-424.
[18]	Bhandare M, Patil P, Pai V, et al. Peritoneal Carcinomatosis in Colorectal Cancers-Management Perspective Needs a Change[J]. Clin Colorectal Cancer, 2017, 16(2) : e1-e6.
[19]	Stewart CL, Warner S, Ito K, et al. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure？[J]. Curr Probl Surg, 2018, 55(9) : 330-379.
[20]	Sugarbaker PH. Peritonectomy procedures[J]. Surg Oncol Clin N Am, 2003, 12(3) : 703-727，xiii.
[21]	Ihemelandu C, Sugarbaker PH. Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution’s Experience During Two Decades[J]. Ann Surg Oncol, 2017, 24(4) : 898-905.
[22]	Metildi CA, Kaushal S, Luiken GA, et al. Fluorescently labeled chimeric anti-CEA antibody improves detection and resection of human colon cancer in a patient-derived orthotopic xenograft (PDOX) nude mouse model[J]. J Surg Oncol, 2014, 109(5) : 451-458.
[23]	Schaap DP, de Valk KS, Deken MM, et al. Carcinoembryonic antigen-specific, fluorescent image-guided cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer[J]. Br J Surg, 2020, 107(4) : 334-337.
[24]	Dwyer RH, Scheidt MJ, Marshall JS, et al. Safety and efficacy of synchronous robotic surgery for colorectal cancer with liver metastases[J]. J Robot Surg, 2018, 12(4) : 603-606.
[25]	Adam R, Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer[J]. Ann Gastroenterol Surg, 2019, 3(1) : 50-56.
[26]	Montalti R, Tomassini F, Laurent S, et al. Impact of surgical margins on overall and recurrence-free survival in parenchymal-sparing laparoscopic liver resections of colorectal metastases[J]. Surg Endosc, 2015, 29(9) : 2736-2747.
[27]	Al Bandar MH, Kim NK. Current status and future perspectives on treatment of liver metastasis in colorectal cancer[J]. Oncol Rep, 2017, 37(5) : 2553-2564.
[28]	Handgraaf HJM, Boogerd LSF, Hoppener DJ, et al. Long-term follow-up after near-infrared fluorescence-guided resection of colorectal liver metastases: A retrospective multicenter analysis[J]. Eur J Surg Oncol, 2017, 43(8) : 1463-1471.
[29]	Boogerd LS, Handgraaf HJ, Lam HD, et al. Laparoscopic detection and resection of occult liver tumors of multiple cancer types using real-time near-infrared fluorescence guidance[J]. Surg Endosc, 2017, 31(2) : 952-961.
[30]	Hiroshima Y, Lwin TM, Murakami T, et al. Effective fluorescence-guided surgery of liver metastasis using a fluorescent anti-CEA antibody[J]. J Surg Oncol, 2016, 114(8) : 951-958.
[31]	Hollandsworth HM, Nishino H, Turner M, et al. Humanized Fluorescent Tumor-associated Glycoprotein-72 Antibody Selectively Labels Colon-cancer Liver Metastases in Orthotopic Mouse Models[J]. In Vivo, 2020, 34(5) : 2303-2307.
[32]	Bodet-Milin C, Bailly C, Touchefeu Y, et al. Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches[J]. Front Med (Lausanne), 2019, 6 : 124.

Please choose a citation manager

Content to export